| Roche set to finalise $1.5bn Poseida Therapeutics takeover |
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche on Wednesday said it had been accepted for payment on 65 million shares in Poseida, which specialises in complex immune cell therapies for types of blood cancer. |
proactiveinvestors.com |
2025-01-08 08:32:24 |
Czytaj oryginał (ang.) |
| Roche to complete acquisition of U.S. biopharma company Poseida |
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp. |
reuters.com |
2025-01-08 03:35:40 |
Czytaj oryginał (ang.) |
| PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones, is fair to Poseida shareholders. Halper Sadeh encourages Poseida shareholders to click here to learn more about their le. |
businesswire.com |
2024-12-20 11:24:00 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? |
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-12-13 12:15:21 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting |
Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today will highlight interim clinical data from its Phase 1 trial of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma (RRMM), including new profiling of patient responses from Arm C, an optimized lymphodepletion arm. The P-BCMA-ALLO1 data are being presented, along with two additional Company poster presentations covering new preclinical data for P-CD19CD20-ALLO1 and a patient case study demonstrating the reactivation of a Poseida autologous CAR-T therapy with a T-cell engager, at the 66th ASH Annual Meeting and Exposition being held in San Diego on December 7-10, 2024. |
prnewswire.com |
2024-12-09 14:00:00 |
Czytaj oryginał (ang.) |
| Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? |
From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. |
zacks.com |
2024-11-28 12:56:22 |
Czytaj oryginał (ang.) |
| POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Poseida Therapeutics, Inc. (NasdaqGS: PSTX) to Roche Holdings, Inc. Under the terms of the proposed transaction, shareholders of Poseida will receive $9.00 in cash plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash (upon achieveme. |
businesswire.com |
2024-11-27 20:14:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet |
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-27 13:00:48 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? |
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-11-27 12:16:13 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX |
NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Poseida Therapeutics, Inc. (NASDAQ: PSTX ), relating to the proposed merger with Roche Holdings, Inc. Under the terms of the agreement, Poseida Therapeutics will be acquired at a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share. |
prnewswire.com |
2024-11-26 22:50:00 |
Czytaj oryginał (ang.) |
| Poseida shares triple on Tuesday, boosted by Roche collaboration |
Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding (SWX: ROG) said it will buy the clinical-stage biopharmaceutical company for about $1.5 billion. Roche's offer values each share of Poseida Therapeutics at $9.0 that translates to a more than 200% premium on their previous close. |
invezz.com |
2024-11-26 15:17:24 |
Czytaj oryginał (ang.) |
| Why This Gene-Therapy Company's Stock Is Rising 228% |
Poseida Therapeutics, a cell therapy company, is being acquired by Roche in a $1.5 billion deal. |
barrons.com |
2024-11-26 13:10:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Poseida (Nasdaq: PSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, the stockholders of Poseida will receive only $9.00 per share, plus a non-tradeable CVR to receive certain conting. |
businesswire.com |
2024-11-26 11:22:00 |
Czytaj oryginał (ang.) |
| Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details |
On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity value of approximately $1.5 billion on a fully diluted basis. |
benzinga.com |
2024-11-26 11:07:08 |
Czytaj oryginał (ang.) |
| PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones, is fair to Poseida shareholders. Halper Sadeh encourages Poseida shareholders to click here to learn more about their le. |
businesswire.com |
2024-11-26 09:23:00 |
Czytaj oryginał (ang.) |
| Roche to acquire US-based Poseida Therapeutics |
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday. |
reuters.com |
2024-11-26 03:29:05 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. |
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that it has entered into a merger agreement to be acquired by Roche Holdings, Inc. ("Roche") at a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones. This corresponds to a total equity value of approximately $1.5 billion on a fully diluted basis. |
prnewswire.com |
2024-11-26 03:10:00 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline |
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology Advancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumors Virtual R&D Day featuring partner Astellas Pharma and Poseida's leadership and scientific teams to be held today at 10:00am ET / 7:00am PT SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells (TSCM)-rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT. "We believe Poseida is well positioned to be a cell therapy leader based on the unique capabilities of our proprietary non-viral technology platform and our allogeneic TSCM-rich CAR-T approach," said Kristin Yarema, Ph.D. |
prnewswire.com |
2024-11-14 11:00:00 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know |
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-11-12 15:05:20 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics to Present at Two Upcoming Investor Conferences |
SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 10:20am ET Piper Sandler 36th Annual Healthcare Conference Date: Wednesday, December 4, 2024 Time: 12:00pm ET Webcasts will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation. |
prnewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates |
Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2024-11-07 20:56:16 |
Czytaj oryginał (ang.) |
| Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 |
Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T pipeline before year-end 2024, including presentations at the 66th American Society of Hematology Annual Meeting in December SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2024. "Poseida continues to make excellent progress across all of our key initiatives, highlighted by compelling data presentations from our pipeline of innovative, non-viral allogeneic cell therapy and genetic medicine programs, the expansion and advancement of our collaborations with Roche and Astellas, and our science-backed strategy to apply our platform to the large and growing opportunity for CAR-T in autoimmune diseases," said Kristin Yarema, Ph.D. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |